Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 13/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329063 | 1.00 | F2 (0.43) | F2PRSS1CMA1CTRCF10 | |
| SCHEMBL12605461 | 0.92 | F2 (0.44) | F2PRSS1CMA1CTRCF10 | |
| SCHEMBL16329136 | 0.92 | F2 (0.44) | F2PRSS1CMA1CTRCF10 | |
| SCHEMBL12605507 | 0.90 | CMA1 (0.40) | F2PRSS1CMA1CTRCELANE | |
| SCHEMBL16329060 | 0.90 | CMA1 (0.40) | F2PRSS1CMA1CTRCELANE | |
| SCHEMBL16329122 | 0.89 | CMA1 (0.43) | F2PRSS1CMA1CTRCELANE | |
| SCHEMBL12605502 | 0.89 | CMA1 (0.43) | F2PRSS1CMA1CTRCELANE | |
| SCHEMBL12606123 | 0.87 | F2 (0.38) | F2PRSS1CMA1MEN1KMT2A | |
| SCHEMBL16329157 | 0.87 | F2 (0.38) | F2PRSS1CMA1MEN1KMT2A | |
| SCHEMBL12605389 | 0.86 | CMA1 (0.42) | F2PRSS1CMA1CTRCELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | F2 569/4885PRSS1 5/4885CMA1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.